Novo Nordisk Eyes Recovery in 2026 with Wegovy's New Indication Potentially Exceeding $1 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 03 2026
0mins
Source: Fool
- New Indication Approval: Novo Nordisk's Wegovy has received approval for metabolic dysfunction-associated steatohepatitis (MASH), which is expected to drive sales exceeding $1 billion, particularly in the U.S. market that remains underserved.
- Oral Formulation Innovation: Wegovy's oral version becomes the first weight loss drug approved for daily use, catering to patient preferences and potentially enhancing Novo Nordisk's revenue growth.
- Pipeline Progress: Novo Nordisk is advancing a candidate called amycretin, which is in phase 3 studies and shows promise; successful market entry could help regain its share in the GLP-1 market.
- Reasonable Market Valuation: Despite challenges, Novo Nordisk's stock trades at a forward P/E of 14, below the healthcare sector average of 18.4, indicating investment potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 59.330
Low
42.00
Averages
54.67
High
70.00
Current: 59.330
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Oral Wegovy Launch Shows Promising Potential
- Market Competition Pressure: Novo Nordisk faces intense competition in the weight loss market from Eli Lilly; however, the company aims to expand its market share by launching oral Wegovy, targeting patients who prefer not to inject themselves.
- Sales Growth Potential: Oral Wegovy's prescription volume in the first two weeks post-launch surpassed that of the original Wegovy and Eli Lilly's Zepbound, indicating strong market demand, with projections suggesting peak sales could reach about $3.3 billion for Novo Nordisk.
- Product Line Expansion: Novo Nordisk plans to launch additional weight-loss medications over the next two years, including the recently approved CagriSema and the late-stage clinical trial for Amycretin, further enhancing its competitive edge in the market.
- Investment Opportunity: Despite a significant decline in Novo Nordisk's stock over the past two years, the company's robust product lineup and deep pipeline make its current stock price levels worthy of investor consideration.
Continue Reading
Novo Nordisk Board Member Transition
- Board Member Transition: Thomas Rantzau, who has served on Novo Nordisk's Board of Directors since 2018, is stepping down after 22 years with the company, indicating a shift in corporate governance.
- New Employee Representative: Tanja Villumsen is appointed as the new employee representative on the board, ensuring that employee perspectives continue to be integrated into corporate decision-making, thereby enhancing employee engagement.
- Company Background: Founded in 1923 and headquartered in Denmark, Novo Nordisk focuses on combating serious chronic diseases through scientific breakthroughs and expanding access to medicines, employing approximately 78,500 people and marketing products in around 170 countries.
- Market Presence: Novo Nordisk's B shares are listed on Nasdaq Copenhagen, while its ADRs are traded on the New York Stock Exchange, reflecting the company's strong global market presence and stability.
Continue Reading